NASDAQ
Krystal Biotech, Inc. (KRYS) has a price/sales ratio of 18.34x as of Friday, May 22, 2026. This represents a 10.40% decrease compared to its 12-month average of 20.47x. The price-to-sales ratio evaluates a company's stock price relative to its revenue, useful for valuing companies with little or no earnings.
No price data available for this timeframe.